Research programme: cancer therapeutics - Bristol-Myers Squibb/Exelixis

Drug Profile

Research programme: cancer therapeutics - Bristol-Myers Squibb/Exelixis

Latest Information Update: 04 Mar 2011

Price : $50

At a glance

  • Originator Bristol-Myers Squibb; Exelixis
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Feb 2011 Collaboration is ongoing in the US
  • 22 Jan 2008 Bristol-Myers Squibb exercises its option to develop and commercialise XL 139 under the terms of this collaboration
  • 18 Dec 2006 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top